Articles in international scientific journals with a referee practice

1.     A. Poso, K. Tuppurainen, J. Ruuskanen and J. Gynther: Binding of some dioxins and dibenzofurans to the Ah receptor. A QSAR model based on comparative molecular field analysis (CoMFA). J. Mol. Struct. (Theochem) 1993:282:259.

2.     JC. Callaway, J. Gynther, A. Poso, J. Vepsäläinen and MM. Airaksinen: The Pictet-Spingler Reaction and Biogenic Tryptamines: Formation of Tetrahydro-ß-carbolines at physiological pH. J. Heterocyclic Chem. 1994:31:431-435

3.     A. Poso, K. Tuppurainen and J. Gynther: Modelling of molecular Mutagenicity with comparative molecular field analysis (CoMFA). Structural and electronic properties of MX compounds related to TA100 mutagenicity. J. Mol. Struct. (Theochem) 1994:304:255-260.

4.     P. Kopponen, S. Sinkkonen, A. Poso, J. Gynther and S. Kärenlampi: Sulfur analogues of polychlorinated dibenzo-p-dioxins, dibenzofurans and diphenylethers as inducers of CYP1A1 in mouse hepatoma cell culture and structure-activity relationships. Environ. Toxicol. Chem. 1994:13:15431548.

5.     J. Ketolainen, A. Poso, V. Viitasaari, J. Gynther, J. Pirttimäki, E. Laine and P. Paronen: Changes in solid-state structure of cyclophosphamide monohydrate under mechanical treatment and storage. Pharm. Res. 1995:12:299-304.

6.     A. Poso, A. von Wright and J. Gynther: An empirical and theoretical study on mechanisms of mutagenic activity of hydrazine compounds. Mutat. Res. 1995:332:63-71.

7.     T. Kimonen, M. Pasanen, J. Gynther, A. Poso, T. Järvinen, E. Alhava and R. Juvonen: Competetive inhibition of coumarin 7-hydrozylation by pilocarpine and its interaction with mouse CYP2A5 and human CYP 2A6. Br. J. Pharmac. 1995:116:2625-230.

8.     A. Poso, R. Juvonen, J. Gynther: Comparative molecular field analysis of compounds with CYP2A5 binding affinity. Quant. Struct.-Act. Relat. 1995:14:507-511.

9.     C. Navajas, A. Poso, J. Gynther: CoMFA of flavonoids with antimutagenic activity against 2-amino-4-methylimidazol[4,5-f]quinoline (IQ). Electronic Journal of Theoretical Chemistry (EJTC). 1996:1:1-7.

10.  C. Navajas, T. Kokkola, A. Poso, N. Honka, J. Gynther and J.T. Laitinen: A rhodopsin-based model for melatonin recognition in its G-protein-coupled receptor. Eur. J. Pharmac. 1996:304/1-3:173-183.

11.  C. Navajas, A. Poso, K. Tuppurainen, J. Gynther: Comparative molecular field analysis (CoMFA) of MX compounds using different semi-empirical methods: LUMO field and its correlation with mutagenic activity. Quant. Struct.-Act. Relat. 1996:15:189-193.

12.  E. Suihko, J. Ketolainen, A. Poso, M. Ahlgren, J. Gynther and P. Paronen: Dehydration of theophylline monohydrate: A two step process. Int. J. Pharm. 1997:158:47-55.

13.  A. Bauer-Brandl, M.E. Geoffroy, A. Poso, J. Suurkuusk, E. Wappler and K.H. Bauer: Comparison of experimental methods and theoretical calculations on crystal energies of ‘isoenergetic’ polymorphs of cimetidine. J. Therm. Anal. Calor. 1999:57:7-22

14.  J. Kovalainen, J. Christiaans, A. Poso, J. Vepsäläinen, R. Laatikainen and J. Gynther: ¹H NMR study of putative intramolecular hydrogen bonding for histamine H₃-receptor agonists. Tetrahedron Lett. 1999:40:2425-2428.

15.  R. Juvonen, G. Gynther, M. Pasanen, E. Alhava and A. Poso: Pronounced differences in inhibition potency of lactone and non-lactone compounds between mouse and human coumarin 7-hydroxylases (CYP2A5 and CYP2A6). Xenobiotica 2000:30:81-92.

16.  JT. Kovalainen, JA Christiaans, R. Ropponen, A. Poso, M. Peräkylä, J. Vepsäläinen, R. Laatikainen and J. Gynther: A proton relay process as the mechanism of activations of the histamine H3-receptor determined by 1H-NMR and ab initio quantum mechanical calculations. Journal of the American Chemical Society 2000:122:6989-6996

17.  E. Suihko, A. Poso, O. Korhonen, J. Gynther, J. Ketolainen and P. Paronen: Deformation behaviour of tolbutamide, hydroxypropyl-ß-cyclodextrin and their physical and molecular dispersions. Pharm Res. 2000:17:942-8.

18.  J. Päivärinta, S. Karlsson, M. Hotokka and A. Poso: Calculated and measured vibrational frequencies in an alkanoic adic-alkylamine complex. Chem. Phys. Lett. 2000:327:420-424

19.  A. Poso, J. Gynther and R. Juvonen: A Comparative Molecular Field Analysis of cytochrome P450 2A5 and 2A6 inhibitors. J. Comp-Aid. Mol. Des. 2001:15:195-202

20.  J. Päivärinta, S. Karlsson, A. Poso, M. Hotokka: Calculated molecular properties for different alkanoic acid-alkylamine complexes: A comparison with measured FTIR and Raman spectra. Chemical Physics 2001:263:127-38

21.  S. Karlsson, J. Päivärinta, R. Friman, A. Poso, M. Hotokka, S. Backlund: Characterization of the Phase Behaviour and Complexation in the Heptanoic Acid-Heptylamine-Water System. J. Phys. Chem. 2001:105:7944-7949

22.  M. Tarvainen, R. Sutinen, M. Kinnunen, P. Paronen, A. Poso: Predicting Plasticization Efficiency from Three-Dimensional Molecular Structure of the Polymer Plasticizer. Pharm. Res. 2001:18:1760-1766

23.  J. Päivärinta, A. Poso, M. Hotokka E. Muttonen: Molecular Dynamics of Steroid Structures in Different Solvents: Crystal growth & Design 2002:2:121-126

24.  J.I. Venäläinen, R.O. Juvonen, M.M. Forsberg, A. Garcia-Horsman, A. Poso, E.A. A. Wallen, J. Gynther, P.T. Männistö:  Substrate-Dependent, Nonhyperbolic Kinetics of Pig Brain Prolyl Oligopeptidase and its Tight Binding Inhibition by JTP-4819. Biochem Pharmacol. 2002:64:463-471.

25.  M. Rahnasto, H. Raunio, A. Poso, R.O. Juvonen: More Potent Inhibition of Human CYP2A6 than Mouse CYP2A5 Enzyme Activities by Derivatives of Phenylethylamine and Benzaldehyde. Xenobiotica 2003:33:529-539

26.  A. Asikainen, J. Tarhanen, A. Poso, M. Pasanen, E. Alhava, RO Juvonen: Predictive value of Comparative Molecular Field Analysis modelling of naphthalene inhibition of human CYP2A6 and mouse CYP2A5 enzymes. Toxicology in Vitro 2003:17:449-455

27.  J. Jyrkkärinne, J. Mäkinen, J. Gynther, H. Savolainen, A. Poso, P. Honkakoski: Molecular Determinants of Steroid Inhibition for Constitutive Androstane Receptor CAR. J. Med. Chem.  2003:46:4687-4695

28.  A. Tervo, T.H. Nyrönen, T. Rönkkö, A. Poso: A Structure-Activity Relationship Study of Catechol-O-Methyltransferase Inhibitors: Combining Molecular Docking and 3D QSAR Methods. J. Comp.  Aid. Mol. Des. 2003:17:797-810

29.  L. Tuovinen, S. Peltonen, M. Liikola, M. Hotakainen, M. Lahtela-Kakkonen, A. Poso, K. Järvinen: Drug release from starch-acetate microparticles and films with and without incorporated a-amylase. Biomaterials  2004 :25:4355-4362

30.  A. Tervo, T.H. Nyrönen, T. Rönkkö, A. Poso: Comparing The Quality and Predictiveness Between 3D QSAR Models Obtained from Manual and Automated Alignment , J. Chem. Inf. Comput. Sci. 2004:44:807-816

31.  O.M.H. Salo, M. Lahtela-Kakkonen, J. Gynther, T. Järvinen and A. Poso: Development of a 3D Model for the Human Cannabinoid CB1 Receptor, J. Med. Chem. 2004:47:3048-3057

32.  A.J. Tervo, S. Kyrylenko, P. Niskanen, A. Salminen, J. Leppänen, T.H. Nyrönen, T. Järvinen, A. Poso: An In Silico Approach to Discovering Novel Inhibitors of Human Sirtuin Type 2. J. Med. Chem. 2004:47:6292 - 6298.

33.  M. Rahnasto, A. Poso, H. Raunio, R.O. Juvonen: QSAR Analysis of Inhibitors of the Nicotine Metabolizing CYP2A6 Enzyme. J. Med. Chem. 2005:48:440-449.

34.  B.Windshügel, J. Jyrkkärinne, A. Poso, P. Honkakoski, W. Sippl: Molecular dynamics simulations of the human CAR ligand binding domain: Deciphering the molecular basis for constitutive activity. J. Mol. Mod. 2005:11:69-79

35.  E. Suihko, R. T. Forbes, O. Korhonen, J. Ketolainen, P. Paronen, J. Gynther, A. Poso: Prediction of Contact Angle for Pharmaceutical Solids from Their Molecular Structure.  J. Pharm. Sci, 2005:94:745-758

36.  T. Kokkola, O. Salo, A. Poso,  J.T. Laitinen: The functional role of cysteines adjacent to the NRY motif of the human MT1 melatonin receptor, J. Pineal Res. 2005:39:1-11.

37.  J. Jyrkkärinne, B. Windshügel, J. Mäkinen, M. Ylisirniö, M. Peräkylä, A. Poso, W. Sippl, P. Honkakoski: Amino Acids Important for Ligand Specificity of the Human Constitutive Androstane Receptor. J. Biol. Chem. 2005:280:5960-5971

38.   K. Raitio, O. Salo, T. Nevalainen, A. Poso, T. Järvinen: Targeting the Cannabinoid CB2 Receptor: Mutations, Modeling and Development of CB2 Selective Ligands. Review. Curr. Med. Chem. 2005:12:1217-1237

39.  J. Savinainen, T. Kokkola, O. Salo, A. Poso, T. Järvinen, JT. Laitinen: Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor. Br. J. Pharmacol. 2005 145:636-645

40.  M.S. Saario, O.M.H. Salo, T. Nevalainen, A.Poso, J.T. Laitinen, T.Järvinen, R.Niemi: Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes. Chemistry & Biology. 2005:12:649-656

41.  B.v. Veen, J. Pajander, K. Zuurman, R. Lappalainen, A. Poso, H.W. Frijlink, J. Ketolainen: The effect of powder blend and tablet structure on drug release mechanisms of hydrophobic starch acetate matrix tablets. Eur. J. Pharm. Biopharm. Eur. J. Pharm. Biopharm. 2005: 61:149-157

42.  L.E. Korhonen,  M. Rahnasto, N.J. Mähönen, C. Wittekindt, A. Poso, R.O. Juvonen, H. Raunio: Predictive 3D-QSAR of CYP1A2 Inhibitors. J. Med. Chem. 2005:48:3808-3815

43.  A. Tervo, T. Rönkkö, T. Nyrönen, A. Poso: BRUTUS: Optimization of a Grid-Based Similarity Function for Rigid-Body Molecular Superposition. I. Alignment and Virtual Screening Applications. J. Med. Chem. 2005:48:4076-4086

44.  E.M. Jarho, E.A.A. Wallén, J.A.M. Christiaans, M.M. Forsberg, J.I. Venäläinen, P.T. Männistö, J. Gynther, A. Poso: Dicarboxylic Acid Azacycle L-Prolyl-pyrrolidine Amides as Prolyl Oligopeptidase Inhibitors and 3D QSAR of the Enzyme-Inhibitor Interactions. J. Med. Chem. 2005:48:4772-4782

45.  O.M.H. Salo, K.H. Raitio, J.R. Savinainen, T. Nevalainen, M. Lahtela-Kakkonen, J.T. Laitinen, T. Järvinen, A. Poso: Virtual screening of novel CB2 ligands using a comparative model of the CB2 receptor.  J Med Chem. 2005:48:7166-71

46.  J.I. Venäläinen, E.A.A. Wallen, A. Poso, J.A. Garcia-Horsman, P.T. Männistö: Synthesis and Characterization of the Novel Fluorescent Prolyl Oligopeptidase Inhibitor 4-Fluoresceinthiocarbamoyl-6-aminocaproyl-L-prolyl-2(S)-(Hydroxy-acetyl)-pyrrolidine. J. Med. Chem. 2005:48:7093-7095

47.  O. Korhonen, S. Matero, A. Poso, J. Ketolainen: Partial least square projections to latent structures analysis (PLS) in evaluating and predicting drug release from starch acetate matrix tablets. J. Pharm. Sci. 2005:94:2716-2730

48.  T. Parkkari, O.M.H. Salo, K.M. Huttunen, J.R. Savinainen, J.T. Laitinen, A.Poso, T. Nevalainen, T. Järvinen: Synthesis and CB1 receptor activities of dimethylheptyl derivatives of 2-arachidonoyl glycerol (2-AG) and 2-arachidonyl glyceryl ether (2-AGE). Bioorganic & Medicinal Chemistry, 2006:14:2850-2858

49.  O.M.H. Salo, J.R. Savinainen, T. Parkkari, T. Nevalainen, M. Lahtela-Kakkonen, J. Gynther, J.T. Laitinen, T. Järvinen, A. Poso: 3D-QSAR studies on Cannabinoid CB1 Receptor agonists: G-protein activation as biological data. J. Med. Chem. 2006:49:554-566

50.  K.H. Raitio, J.R. Savinainen, J. Vepsäläinen, J.T. Laitinen, A. Poso, T. Järvinen, T. Nevalainen: Synthesis and SAR Studies of 2-Oxoquinoline Derivatives as CB2 Receptor Inverse Agonists. J. Med. Chem. 2006:49:2022-2027.

51.  S.M. Saario, A.Poso, R.O. Juvonen, T.Järvinen, O.M.H. Salo-Ahen: Fatty Acid Amide Hydrolase Inhibitors from Virtual Screening of the Endocannabinoid System. J Med Chem. 2006: 49:4650-4656.

52.  T. Rönkkö, A.J. Tervo, J. Parkkinen, A. Poso: BRUTUS: Optimization of a Grid-Based Similarity Function for Rigid-Body Molecular Superposition. II. Description and Characterization. J. Comp-Aid. Mol. Design 2006:20:227-236

53.  T. Huhtiniemi, C. Wittekindt, T. Laitinen, J. Leppänen, A. Salminen, A. Poso, M. Lahtela-Kakkonen: Comparative and pharmacophore model for deacetylase SIRT1. J. Comp-Aid. Mol. Design 2006 accepted

54.  A. Poso, P. Honkakoski: Ligand recognition by drug-activated nuclear receptors PXR and CAR: structural, site-directed mutagenesis and molecular modeling studies. Mini Rev. Med. Chem. 2006:6:937-947

Articles in international scientific compilation works and in international scientific conference proceedings with a referee practice

1.     J. Ketolainen, E. Suihko, A. Poso, M. Ahlgren, J. Gynther and P. Paronen: Characterization of physical properties of theophylline and its polymorphs: 14^th Pharmaceutical Technology Conference, Barcelona, Spain, 1995:3:109-115.

2.     E. Suihko, A. Poso, J. Ketolainen, J. Gynther, P. Paronen: Partial least squares (PLS) analysis in prediction of contact angels for pharmaceutical materials. 15^th Pharmaceutical Technology Conference, Oxford, U.K. 19-23.3.1996:2a:239-264.

3.     Salo OMH, Käsnänen H, Jöhren K, Höltje H-D, Järvinen T, Poso A: Molecular dynamics simulations of the human cannabinoid CB1 receptor model in a DPPC bilayer. In: EuroQSAR 2004 QSAR & Molecular Modelling in Rational Design of Bioactive Molecules. pp. 435-436. Ed. Aki (Sener) E, Yalcin I, Baskent Klise ve Matbaacilik, Ankara, Turkey, 2005

Oral presentation in international conferences

1.     Plasticisers, starch acetate, pharmaceutical chemistry and Volsurf-mission imposible. In the 14th European Symposium on Quantitative Structure-Activity Relationships 8th - 13th September 2002 Bournemouth International Conference Centre, Bournemouth, UK.

2.     Virtual Screening and Molecular Databases: a SIRT2 Case. In the 3rd International Symposium on Computational Methods in Toxicology and Pharmacology Integrating Internet Resources (CMTPI-2005), 29th October - 1st November 2005, Shanghai, P.R. China